Myomo Inc (MYO)
XASE:MYO
Want to see MYO full AI Analyst Report?
MYO Stock Chart & Stats
$0.86
-$0.13(-1.86%)
At close: 4:00 PM EST
$0.86
-$0.13(-1.86%)
Day’s Range― - ―
52-Week Range$0.61 - $2.89
Previous CloseN/A
Volume192.17K
Average Volume (3M)795.60K
Market Cap
$52.93M
Enterprise Value$49.68M
Total Cash (Recent Filing)$15.70M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding38,638,653
10 Day Avg. Volume1,360,657
30 Day Avg. Volume795,595
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda-4.14
Forecast
1Y Price Target
$3.67Price Target Upside326.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$44.43M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & Healthy Gross MarginsSustained multi-year revenue growth (~69% TTM) combined with consistently high gross margins (~66% TTM) indicates durable unit economics. This supports scalable revenue expansion and the potential for operating leverage as fixed costs are spread across higher volumes, improving long-term profitability prospects.
Shift Toward Recurring RevenueA rapid shift to recurring patient sources (49% of Q1 revenue versus 25% prior year) increases revenue predictability and lifetime customer value. Durable recurring streams reduce sales volatility, lower customer acquisition pressure over time, and improve planning for service, supply chain and working-capital needs.
Expanded Payer Access And Unit Cost ReductionsBroader payer contracts (e.g., Elevance, covered lives expanded to 158M) materially improve authorization rates and addressable market. Concurrent product cost savings (mobile app lowering materials ~10%) enhance margins per unit, together strengthening long-term commercial scalability and reimbursement-driven demand conversion.
Bears Say
Persistent UnprofitabilityDespite revenue gains, the company reports sustained net losses and negative margins (~-37% TTM). Persistent unprofitability signals structural operating-cost or scale issues; unless operating expenses or margins improve materially, the business will struggle to generate sustainable earnings and retained capital over the medium term.
Negative Cash Generation And High Cash BurnMaterial negative operating and free cash flow (OCF ~-14M, FCF ~-17M TTM) indicates ongoing cash burn that is larger than operating improvements to date. This structural cash deficit increases dependence on external funding and heightens dilution or refinancing risk absent sustained margin gains or slower cash outlays.
Elevated Leverage And Balance Sheet StressLeverage spiked materially (debt/equity ~1.70 in 2025, only partially improved to ~0.89 TTM), signaling increased financial risk. Higher debt amplifies interest and refinancing exposure, limits strategic flexibility, and can constrain investment in commercialization or R&D if cash flow recovery lags expectations.
Myomo News
MYO FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was $0.60 and its highest was $2.89 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is $52.93M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Aug 11, 2026 which is in 58 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on May 07, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.044.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.1.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 38,638,653 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went down -5.052%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in MYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (326.36% Upside)
$3.67 (326.36% Upside)
Blogger Sentiment
Bullish
MYO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 62.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $322.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.92%
12-Months-Change
Fundamentals
Return on Equity
-114.87%
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Myomo Inc
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
MYO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.View all MYO earnings summariesMYO Stock 12 Month Forecast
Average Price Target
$3.67
▲(326.36% Upside)
Technical Analysis
Ownership Overview
13.32% Insiders
5.61% Mutual Funds
10.88% Other Institutional Investors
63.32% Public Companies and
Individual Investors